Clinical Observation Of Shenqi Guanxin Prescription In Treating Chronic Heart Failure Of Coronary Heart Disease With Qi Deficiency And Blood Stasis Syndrome

Objective:By observing the observation indexes of Shenqi Guanxin Prescription in patients with chronic heart failure of coronary heart disease with qi deficiency and blood stasis syndrome,the efficacy and safety of Shenqi Guanxin Prescription in clinical treatment of chronic heart failure of coronary heart disease were evaluated,which provided a certain basis for clinical medication.Methods:A total of 72 patients with coronary heart disease and chronic heart failure who met the inclusion criteria were collected and randomly divided into two groups,including 36 patients in the treatment group(Shenqi Guanxin prescription combined with conventional western medicine treatment)and 36 patients in the control group(conventional western medicine treatment).The course of treatment was1 month.By observing and recording the changes of NT-pro BNP,left ventricular ejection fraction,cardiac function classification,non-invasive haemodynamic indexes,total score of TCM syndromes and quality of life score before and after treatment,the clinical efficacy was evaluated by data statistics,and the safety index was monitored to judge its safety.Results:1.Efficacy of cardiac function grading:The cardiac function grading of both groups was improved,and the treatment group was batter than the control group(P value < 0.05).2.Efficacy of left ventricular ejection fraction:The left ventricular ejection fraction of both groups was improved,and the treatment group was batter than the control group(P value < 0.01).3.Efficacy of NT-pro BNP:NT-pro BNP of both groups was decreased,with the decrease in the treatment group being greater than that in the control group(P value <0.05).4.Efficacy of TCM syndrome score:.The TCM syndrome scores of both groups decreased compared with those before treatment,with the decrease in the treatment group being greater than that in the control group(P value <0.01).5.Quality of life score:The quality of life scores of the two groups were decreased,and the treatment group was batter than the control group(P value< 0.01).6.Efficacy of non-invasive haemodynamic:Both treatment regimens improved non-invasive haemodynamic parameters,with the increase in CO and CI in the treatment group being greater than in the control group(P value <0.05).7.Security:There were no adverse reactions in the two groups during treatment.The safety index of the two groups of patients were not significantly changed compared with those before treatment.Conclusion:Shenqi Guanxin Prescription can significantly improve the cardiac function grading,TCM syndrome score,NT-pro BNP level,left ventricular ejection fraction and improve the quality of life of patients with chronic heart failure of coronary heart disease and qi deficiency and blood stasis syndrome.It is safe and reliable,without obvious adverse reactions,and is worthy of clinical application.